Ascension announces leadership changes, CEO departure

Three executives at Ascension, a nonprofit health system based in St. Louis, are departing from their roles, Ascension President and CEO Anthony Tersigni, EdD, FACHE, said in an announcement.

CEO of Ascension Healthcare, Patricia Maryland, DrPH, will remain in her role through June 30 before departing. On July 1, Ascension Healthcare will eliminate the role of CEO entirely. Maryland will focus her work primarily in Washington, D.C., to support the hospital transition from acute care to a community-based health village model.

Joseph Impicciche, JD, MHA, will step into the newly created role of president and COO. He has served as executive vice president and general counsel of Ascension since 2004.

In addition, John Doyle, executive vice president of the health system, will retire at the end of the fiscal year. David Pryor, MD, Ascencion’s chief clinical officer, will also retire at the end of the fiscal year, according to the announcement.

The healthcare organization is also taking other steps to restructure its leadership “to create stronger connections and greater alignment between its strategic vision and its ability to effectively implement its Advanced Strategic Direction,” according to Tersigni.

The leadership change comes nearly a year after CEO Maryland stated she spent much of her time working on leadership development.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.